Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 16, 2022 06:30 ET | Source: Cerevel Therapeutics

Cerevel Therapeutics to Report Fourth Quarter 2021 Financial Results and Pipeline Update on Tuesday, March 1, 2022

CAMBRIDGE, Mass., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced...
February 15, 2022 06:30 ET | Source: Cerevel Therapeutics

Cerevel Therapeutics Announces Positive Topline Results for Darigabat in Phase 1 Clinical Trial in Acute Anxiety

In healthy volunteers, both the 7.5 mg and 25 mg twice-daily doses of darigabat demonstrated a clinically meaningful and statistically significant improvement in the Panic Symptoms List score after...
January 10, 2022 06:30 ET | Source: Cerevel Therapeutics

Cerevel Therapeutics to Present at 40th Annual JP Morgan Healthcare Conference: Additional Details of Phase 2 Program for Emraclidine (CVL-231) in Schizophrenia to be Presented

Emraclidine now the international nonproprietary name (INN) for CVL-231, an M4-selective positive allosteric modulator in development for schizophrenia Company expects to initiate Phase 2 program for...
January 03, 2022 07:00 ET | Source: Cerevel Therapeutics

Cerevel to Present at the 40th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a global company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today...
December 16, 2021 07:00 ET | Source: Cerevel Therapeutics

Cerevel Therapeutics and Herophilus Announce Collaboration to Evaluate Novel Neuroimmune Modulating Therapeutic Strategies for Schizophrenia

CAMBRIDGE, Mass. and SAN FRANCISCO, Dec. 16, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience...
November 10, 2021 06:30 ET | Source: Cerevel Therapeutics

Cerevel Therapeutics Reports Third Quarter 2021 Financial Results and Pipeline Updates

Phase 1 data for darigabat in acute anxiety now expected by the end of Q1 2022 Submissions of additional PK/PD data for CVL-231 in schizophrenia accepted for presentation at the Annual Meeting of the...
November 01, 2021 06:30 ET | Source: Cerevel Therapeutics

Cerevel Therapeutics to Participate at Upcoming Virtual Investor Conferences

CAMBRIDGE, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that...
October 20, 2021 06:30 ET | Source: Cerevel Therapeutics

Cerevel Therapeutics to Report Third Quarter 2021 Financial Results on Wednesday, November 10, 2021

CAMBRIDGE, Mass., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced...
October 07, 2021 07:00 ET | Source: Cerevel Therapeutics

Cerevel Therapeutics Hosts Virtual R&D Event to Review CVL-871 in Dementia-Related Apathy and Provide Update on CVL-231 for the Treatment of Schizophrenia

Live webcast today from 10:00 to 11:30 a.m. ET CAMBRIDGE, Mass., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain...
September 21, 2021 17:00 ET | Source: Cerevel Therapeutics

Cerevel Therapeutics Announces Departure of CFO Kathy Yi

Current Chief Accounting Officer Mark Bodenrader named as interim CFO Search underway for permanent successor CAMBRIDGE, Mass., Sept. 21, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq:...